Viridian Therapeutics Inc.’s (VRDN) Biologics License Application for Veligrotug for the treatment of thyroid eye disease is under priority review by the FDA, with a decision date set for June 30, 2026.Thyroid eye disease, or TED in short, is an autoimmune condition characterized by inflammation, growth, and damage to tissues around and behind the eyes.People living with TED experience proptosis, redness, swelling, diplopia, and lid retraction. An estimated 190 thousand people in the US alone have moderate to severe TED.Amgen's Tepezza, the first and only approved therapy for the treatment of TED in the U.S., is administered to patients intravenously once every three weeks over a course of eight infusions. Unlike Tepezza’s eight-infusion regimen, Veligrotug is designed to be administered once every three weeks over a course of five infusions.VRDN closed Tuesday’s (June 2, 2026) trading at $15.87, down 6.43%.